EVO ▼ -2.2% - Evotec SE $EVO - Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies Evotec Biologics has advanced a monoclonal antibody candidate against orthopoxvirus into Phase 1 clinical studies under sponsorship by the U.S. Department of Defense, a development that typically signals progress in the company's pipeline. Despite this clinical advancement, EVO shares declined 2.2% today, suggesting the market may have already priced in this milestone or investors had higher expectations for the announcement. 09-SEP-2026 02:01 AM ET